Verapamil increases anti-tuberculosis activity of bedaquiline Researchers have shown that giving bedaquiline along with the calcium channel blocker verapamil can result in more potent antibacterial effects.…
Redesigned aminoglycoside may eliminate risk of hearing loss Researchers have diminished the toxicity of the aminoglycoside sisomicin — which can cause hearing damage or loss — by altering its molecular structure.…
2014: The Pharmaceutical Journal’s news in review Looking back at some of the biggest news stories from the past year. …
Early effects of yellow fever virus examined In the first 72 hours after infection, the yellow fever virus induces changes in the expression of nearly 800 genes, scientists have discovered.…
New roles explored for nucleoside reverse transcriptase inhibitors New research suggests nucleoside reverse transcriptase inhibitors (NRTIs) have intrinsic anti-inflammatory activity through suppression of NLRP3 inflammasome.…
Lipophilic bisphosphonates used to target lung cancer A new generation of lipophilic bisphosphonates has been designed to target cancer, with a zoledronic acid analogue demonstrating efficacy against lung adenocarcinoma.…
Role for memantine in treating binge-eating disorder Research findings support a role for memantine as a potential pharmacological treatment for binge-eating disorder.…
Breakthrough in targeting KRAS gene mutation implicated in many cancers Researchers have identified an agent that interferes with the cell signalling protein KRAS and which produces a dose-dependent reduction in tumour growth in a mouse model.…
Experimental drug holds promise for Ewing sarcoma patients Strategy for interfering with DNA repair offers potential treatment for Ewing sarcoma.…
Vaccine for human respiratory syncytial virus on the horizonA vaccine being developed to protect against human respiratory syncytial virus may offer hope in preventing this major cause of infant infection.…